Loading...
•
Jun 30, 2023
NextCure Q2 2023 Earnings Report
NextCure reported financial results for the second quarter of 2023 and provided a business update.
Key Takeaways
NextCure reported cash, cash equivalents, and marketable securities of $130.6 million as of June 30, 2023. Net loss for the quarter ended June 30, 2023, was $17.9 million, consistent with the net loss for the quarter ended June 30, 2022.
Continued enrollment in the Phase 1b/2 clinical trial evaluating NC410 in combination with pembrolizumab in patients with immune checkpoint naive or checkpoint refractory solid tumors.
Phase 1b data for NC410 are expected in the fourth quarter of 2023.
Phase 1b update for NC762 is expected in the fourth quarter of 2023.
Phase 1a update for NC525 is expected in the fourth quarter of 2023.
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...